Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 4/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 4/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 4/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371223 | 0.81 | TDO2 (0.38) | TDO2CSNK2A1TTR | |
| SCHEMBL571197 | 0.77 | KMT2A (0.44) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL571166 | 0.70 | PIM1 (0.45) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL19642290 | 0.67 | NMUR2 (0.41) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL15470534 | 0.67 | GABRP (0.43) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL2371448 | 0.67 | PIM1 (0.48) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL24738581 | 0.65 | AHR (0.53) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL12213465 | 0.65 | KMT2A (0.46) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL2370587 | 0.64 | MAPT (0.54) | CSNK2A2CSNK2B | |
| SCHEMBL24738578 | 0.64 | AHR (0.44) | PIM1CSNK2A2CSNK2BPIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883782-B2 | Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2547685-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | Amgen Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | TDO2 4125/4885PIM1 4303/4885CSNK2A2 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.